Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02596035 · ClinicalTrials.gov registry record · Phase 4
An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma
A Phase 4 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 4
- Development phase
- 197
- Enrollment target
NCT02596035 is a Phase 4 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 197 participants.
The verdict
NCT02596035, a Phase 4 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 197 participants
- Enrollment target
Study Summary
This study will generate safety data on Nivolumab given by itself in treatment of advanced Renal Cell Carcinoma (RCC). The primary objective of this study is to assess immune related side effects, also known as immune-mediated adverse events (IMAEs), in patients treated with Nivolumab.
Interventions
- DRUG Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2016-01-08 |
| Est. Completion | 2021-05-24 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02596035
The ClinicalTrials.gov registry entry for NCT02596035 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 197 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nivolumab is the first listed.
NCT02596035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02596035 about?
NCT02596035 is a clinical study titled "An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma". This study will generate safety data on Nivolumab given by itself in treatment of advanced Renal Cell Carcinoma (RCC). The primary objective of this study is to assess immune related side effects, also known as immune-mediated adverse events (IMAEs), in patients treated with Nivolumab.
What is the current status of trial NCT02596035?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 197 participants. The study started on 2016-01-08. Estimated completion is 2021-05-24.
What interventions are being tested in trial NCT02596035?
The interventions under investigation include: Nivolumab (DRUG).
Who is sponsoring clinical trial NCT02596035?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.